Therapeutic Misconception in ALS
Some subjects who participate in trials of novel therapies mistakenly believe that the trial is designed to maximize benefit to the individual subjects -- thus laboring under the Therapeutic Misconception. Patients with ALS have a uniformly fatal disease, and some worry that ALS patients are even more prone to the therapeutic misconception.
Our speakers will discuss the evidence for a therapeutic misconception in ALS trials, and consider more broadly how the therapeutic misconception should be addressed by investigators and institutional review boards.
Scott Kim, MD, PhD, Department of Bioethics, National Institutes of Health
James D. Berry, MD, MPH, Unit Chiefm ALS Multidisciplinary Clinic, Massachusetts General Hospital
Spencer Hey, PhD, Research Fellow, Brigham and Women's Hospital Instructor, Center for Bioethics Harvard Medical School
Ways to Join
This event is free and open to the public, but if you are not affiliated with Harvard you must register to attend. Please bring proof of ID to the event due to building security. REGISTER NOW!
Can't attend in person? Watch the webcast live on bioethics.hms.harvard.edu.
Neuroethics Seminar Series
This event is part of a series hosted by the Center for Biothics at Harvard Medical School. For more information, visit the website.
The International Neuroethics Society
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School
Center for Law, Brain, and Behavior, MGH
Institute for the Neurosciences, BWH
Center for Brain Science, Harvard University
Department of Neurobiology, Harvard Medical School
With funding from
Mind Brain Behavior Interfaculty Initiative, Harvard University
The Harvard Brain Initiative Collaborative Seed Grant Program